Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 120


Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens.

Eminaga O, Hinkelammert R, Abbas M, Wötzel F, Eltze E, Bettendorf O, Boegemann M, Semjonow A.

Urology. 2015 Oct;86(4):798-804. doi: 10.1016/j.urology.2015.07.029. Epub 2015 Aug 6.


Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2015 Feb 11;16(2):3856-69. doi: 10.3390/ijms16023856.


Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20.


Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.

Eminaga O, Bögemann M, Breil B, Titze U, Wötzel F, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Nov;32(8):1317-26. doi: 10.1016/j.urolonc.2014.04.018. Epub 2014 Jun 2.


The need for harmonized structured documentation and chances of secondary use - results of a systematic analysis with automated form comparison for prostate and breast cancer.

Krumm R, Semjonow A, Tio J, Duhme H, Bürkle T, Haier J, Dugas M, Breil B.

J Biomed Inform. 2014 Oct;51:86-99. doi: 10.1016/j.jbi.2014.04.008. Epub 2014 Apr 18.


Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K.

Eur Urol. 2014 Aug;66(2):243-50. doi: 10.1016/j.eururo.2014.03.011. Epub 2014 Mar 21.


Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies.

Eminaga O, Hinkelammert R, Abbas M, Titze U, Eltze E, Bettendorf O, Wötzel F, Bögemann M, Semjonow A.

BJU Int. 2015 Jul;116(1):57-64. doi: 10.1111/bju.12691. Epub 2015 Apr 17.


Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study.

Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2014 Feb;34(2):665-9.


Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patients.

Hinkelammert R, Eminaga O, Bettendorf O, Eltze E, Abbas M, Hertle L, Semjonow A.

Urol Oncol. 2014 May;32(4):403-12. doi: 10.1016/j.urolonc.2013.10.001. Epub 2013 Dec 12.


An electronic specimen collection protocol schema (eSCPS). Document architecture for specimen management and the exchange of specimen collection protocols between biobanking information systems.

Eminaga O, Semjonow A, Oezguer E, Herden J, Akbarov I, Tok A, Engelmann U, Wille S.

Methods Inf Med. 2014;53(1):29-38. doi: 10.3414/ME13-01-0035. Epub 2013 Dec 9.


Linkage of data from diverse data sources (LDS): a data combination model provides clinical data of corresponding specimens in biobanking information system.

Eminaga O, Özgür E, Semjonow A, Herden J, Akbarov I, Tok A, Engelmann U, Wille S.

J Med Syst. 2013 Oct;37(5):9975. doi: 10.1007/s10916-013-9975-y. Epub 2013 Sep 11.


Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.


Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.

Arsov C, Becker N, Hadaschik BA, Hohenfellner M, Herkommer K, Gschwend JE, Imkamp F, Kuczyk MA, Antoch G, Kristiansen G, Siener R, Semjonow A, Hamdy FC, Lilja H, Vickers AJ, Schröder FH, Albers P.

Eur Urol. 2013 Dec;64(6):873-5. doi: 10.1016/j.eururo.2013.05.022. Epub 2013 May 14. No abstract available.


High-grade prostatic intraepithelial neoplasia (HGPIN) and topographical distribution in 1,374 prostatectomy specimens: existence of HGPIN near prostate cancer.

Eminaga O, Hinkelammert R, Abbas M, Titze U, Eltze E, Bettendorf O, Semjonow A.

Prostate. 2013 Jul;73(10):1115-22. doi: 10.1002/pros.22660. Epub 2013 Mar 26.


The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.

Eminaga O, Hinkelammert R, Titze U, Abbas M, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Jan;32(1):32.e17-25. doi: 10.1016/j.urolonc.2012.11.021. Epub 2013 Feb 19.


Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A.

Clin Chem. 2013 Jan;59(1):306-14. doi: 10.1373/clinchem.2012.195784. Epub 2012 Dec 4.


Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.


CMDX©-based single source information system for simplified quality management and clinical research in prostate cancer.

Eminaga O, Abbas M, Hinkelammert R, Titze U, Bettendorf O, Eltze E, Ozgür E, Semjonow A.

BMC Med Inform Decis Mak. 2012 Dec 3;12:141. doi: 10.1186/1472-6947-12-141.


Active surveillance for low-risk prostate cancer.

Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R.

Crit Rev Oncol Hematol. 2013 Mar;85(3):295-302. doi: 10.1016/j.critrevonc.2012.07.005. Epub 2012 Aug 9. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk